Technology in Cancer Research & Treatment最新文献

{"title":"The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).","authors":"Ya-Nan Wang, Chao-Wei Zhang, Yu-Xuan Gao, Xue-Ling Ge","doi":"10.1177/15330338251321349","DOIUrl":"10.1177/15330338251321349","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a malignant hematological disease originating from plasma cells that remains incurable. Autologous stem cell transplantation (ASCT) is an important treatment method for MM. With the development of new drugs, the treatment of MM patients who meet the ASCT criteria has significantly improved, and the median survival time has increased by 8-10 years. The current treatment for MM patients who meet the ASCT criteria consists mainly of the following stages: induction therapy, stem cell collection, stem cell transplantation, and consolidation and maintenance therapy. Even today, long-term disease control remains the goal of MM treatment in clinical practice. In the era of new drugs, early ASCT still results in longer progression-free survival (PFS) and is currently the standard treatment method for young newly diagnosed multiple myeloma (NDMM) patients. Moreover, tandem transplantation can be considered for MM patients with high-risk cytogenetics. This review discusses mainly the role of ASCT in MM, the conditions for patient transplantation, the induction chemotherapy regimen before transplantation, the conditioning regimen, the timing of transplantation, and the effectiveness of tandem transplantation, including maintenance and salvage ASCT after transplantation.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251321349"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening of Germline BRCA1 and BRCA2 Variants in Nigerian Breast Cancer Patients.","authors":"Abimbola F Onyia, Paul Jibrin, Temitope Olatunji-Agunbiade, Ademola Oyekan, AbdulRazzaq Lawal, Adewumi Alabi, Anthonia C Sowunmi, Eben A Aje, Oluwabusayo B Ogunniyi, Ebenezer S Nkom, Opeyemi C De Campos, Oluwakemi A Rotimi, Jelili O Oyelade, Solomon O Rotimi","doi":"10.1177/15330338251333012","DOIUrl":"https://doi.org/10.1177/15330338251333012","url":null,"abstract":"<p><p>BackgroundBreast cancer remains a leading cause of mortality among Nigerian women, with triple-negative breast cancer (TNBC) being particularly prevalent. Variations in BRCA1 and BRCA2 genes remain key risk factors for this disease. However, there are gaps in the frequency and spectrum of these variants in Nigerian populations, as well as a dearth in the local capacity to characterize these variations.ObjectiveThis study aimed at identifying and characterizing the germline variations in BRCA1/2 in Nigerian breast cancer patients and healthy age-matched controls to understand the genetic risk profile of breast cancer in this population.MethodsA prospective case-control study was conducted involving 45 breast cancer patients and 51 controls recruited from four major hospitals. DNA was extracted from blood samples, followed by targeted sequencing of BRCA1/2 exonic and intronic regions using the Ampliseq BRCA panel and Illumina MiSeq platform. Variant calling was performed, clinical significance was evaluated on ClinVar and BRCA Exchange databases, and haplotype analysis was performed using NIH LDlink and Haploview 4.2 software.ResultsPathogenic BRCA1/2 variants were identified in 6.7% of breast cancer patients, all with TNBC and a family history of cancer. Two pathogenic BRCA1 variants were detected: a frameshift deletion BRCA1 c.133_134delAA (p.Lys45 fs) (rs397508857) and a missense variant BRCA1 c.5324T > A (p.Met1775Arg) (rs41293463). A BRCA2 frameshift deletion BRCA2 c.8817_8820del (p.Lys2939 fs) (rs397508010) was also identified. These variants were absent in controls. Haplotype analysis revealed distinct BRCA1 and BRCA2 haplotypes in the breast cancer group.ConclusionThis study identifies key BRCA1/2 pathogenic variants and unique haplotypes in Nigerian breast cancer patients, highlighting the need for population-specific genetic screening. Integrating genetic testing into breast cancer management strategies could facilitate early detection, personalized treatment planning, and genetic counseling in Nigeria.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251333012"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of VEGF-А, Аngiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery.","authors":"Veselin Popov, Gabriela Raycheva, Zhanet Grudeva-Popova","doi":"10.1177/15330338251313945","DOIUrl":"10.1177/15330338251313945","url":null,"abstract":"<p><p>The contemporary concept of carcinogenesis summarizes the role of hypoxia, neoangiogenesis, and hemostasis, including in the stage of progression and metastasis of the tumor process. Metastatic disease is a serious therapeutic challenge for any oncological condition. The purpose of this study was to evaluate the dynamics of specific indicators of neoangiogenesis and hypoxia as potential biomarkers for therapeutic efficacy or risk of disease progression in patients with brain metastases (BM) undergoing robotic stereotactic radiosurgery. Two groups of patients (lung cancer and other types of cancers) with oligometastatic disease and brain metastases were included. The patients (n = 66) were treated CyberKnife system. Human Angiopoietin-2, Hypoxia inducible factor 1 α (HIF-1α) and human Vascular Endothelial Growth Factor-А (VEGF-А) were measured in this prospective longitudinal study. Analysis of human Angiopoietin-2, HIF-1α, human VEGF-A in the post-treatment period showed a statistically significant decrease between the baseline and the 6 months post-treatment time point in both patient groups. The baseline value of serum VEGF-А in the group with lung cancer decreased by 40%, Аngiopoietin-2-by 48%, HIF-1α -by 43%. In the group with other types of cancers, VEGF-А decreased by 54.75%, Аngiopoietin-2-by 52%, HIF-1α -by 39.5%. Despite the significant reduction, the levels remained significantly higher in both groups than in healthy controls. This study underscores the potential of integrating molecular markers like VEGF-A, Angiopoietin-2, and HIF-1α into clinical decision-making to enhance outcomes for patients with brain metastases undergoing RSRS.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251313945"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptional Regulation of NUPR1 by MYH11 Activates PI3 K/AKT and Promotes Bladder Cancer Progression Through Ferroptosis and M2 Polarization of Macrophages.","authors":"Lifeng Zhang, Li Zhang, Zebin Shi, Yuanyuan Mi, Lei Zhang, Xiaokai Shi, Shenglin Gao, Li Zuo","doi":"10.1177/15330338241305434","DOIUrl":"10.1177/15330338241305434","url":null,"abstract":"<p><strong>Background: </strong>NUPR1 is a small molecule protein that plays an important role in tumor progression and drug resistance. Our previous study found that NUPR1 promotes the progression of bladder cancer, but the specific mechanism is still unclear. MYH11 encodes the smooth muscle myosin heavy chain and belongs to the conventional myosin family. MYH11 has been found to be associated with a variety of malignant tumors.</p><p><strong>Methods: </strong>We identified MYH11 as an upstream regulator of NUPR1 using a bioinformatics approach and tested this hypothesis by knocking down MYH11 and ChIP-qPCR. Subsequently, we verified the association of MYH11 and NUPR1 with the PI3 K/AKT pathway by WB. In addition, gene enrichment results showed that the effect of NUPR1 on bladder cancer was related to ferroptosis and M2 macrophage polarization. We examined ferroptosis metabolites in bladder cancer cells overexpressing NUPR1 and expression of the M2 macrophage marker CD206 in NUPR1 overexpression or MYH11 knockdown bladder cancer cells.</p><p><strong>Results: </strong>Bioinformatics results showed that MYH11 was positively correlated with NUPR1, and there may be a mutual binding site at the promoter of NUPR1. Knockdown of MYH11 decreased NUPR1 expression, and ChIP-qPCR showed that MYH11 bound to the promoter of NUPR1. Subsequently, WB results showed that MYH11 knockdown inhibited the PI3 K/AKT pathway, whereas NUPR1 overexpression activated this pathway. After adding ferroptosis activator, the viability of bladder cancer cells decreased, and the content of Fe²⁺ and MDA increased. However, ferroptosis was significantly inhibited after overexpression of NUPR1. Knockdown of MYH11 inhibited M2 macrophage polarization, while overexpression of NUPR1 promoted this process.</p><p><strong>Conclusion: </strong>This study suggests that MYH11 activates the PI3 K/AKT pathway by up-regulating the expression of NUPR1, and promotes bladder cancer progression by inhibiting ferroptosis and promoting M2 polarization of macrophages.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241305434"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboxylesterase 4A Inhibits the Malignant Biological Behavior of Nasopharyngeal Carcinoma via the PI3K/AKT Pathway.","authors":"Qiaoli Chen, Quanxiang Hao, Yanping Yang, Limei Li, Danping Li, Ran Zhao, Wanqi Wei, Lixian Deng, Jiaming Su, Ziyuan Liang, Shiyue Tang, Yaomin Lu, Yushan Liang, Zhe Zhang, Xiaoying Zhou, Xue Xiao, Ping Li, Yi Huang, Weilin Zhao","doi":"10.1177/15330338251319144","DOIUrl":"10.1177/15330338251319144","url":null,"abstract":"<p><strong>Background: </strong>Carboxylesterase 4A (CES4A) belongs to the member of the carboxylesterase family, yet there has been limited research into its malignant biological behavior in malignant tumors. Here, we aim to investigate the expression, cellular biological functions, and the potential underlying mechanism of CES4A in nasopharyngeal carcinoma (NPC).</p><p><strong>Method: </strong>A standardized mean difference (SMD) analysis was used to analyze the dysregulation of CES4A based on the gene expression omnibus (GEO) database. qRT-PCR and immunohistochemical staining (IHC) were used to identify the mRNA and protein levels of CES4A in NPC cell lines and tissues, respectively. CCK-8, colony formation, wound healing and transwell assays were utilized to estimate cellular growth and metastasis, respectively. Western blot was conducted to evaluate the activity of PI3K/AKT signaling pathway.</p><p><strong>Result: </strong>Both mRNA and protein expression of CES4A was significantly diminished both in NPC cell lines and primary tumor tissues. Ectopic expression of CES4A restrains the proliferation, colony formation, migration and invasion of NPC. Additionally, KEGG analysis based on GEO data and high-throughput transcriptome sequencing of cell lines all strongly suggested that CES4A was involved in regulating phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. It was observed that AKT and phosphorylated AKT were remarkably reduced in CES4A overexpressing NPC cells, indicating that PI3K/AKT signaling pathway is hindered by CES4A.</p><p><strong>Conclusion: </strong>CES4A expression is silenced in NPC, functioning as a tumor suppressor by negatively modulating the PI3K/AKT signaling pathway.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251319144"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11800256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>In Vitro</i> Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes.","authors":"Islam Alfreahat, Hamdi Nsairat, Ibrahim Deeb Aldeeb, Ali Al-Samydai, Walhan Alshaer","doi":"10.1177/15330338241312561","DOIUrl":"10.1177/15330338241312561","url":null,"abstract":"<p><strong>Background: </strong>Doxorubicin (DOX) is a potent chemotherapeutic agent for breast cancer, but its effectiveness is often diminished by resistance mechanisms, particularly through p-glycoprotein (P-gp) mediated drug efflux. Clarithromycin (CAM), a macrolide antibiotic, inhibits multiple metabolic pathways including CYP3A and P-gp, potentially countering DOX resistance.</p><p><strong>Objective: </strong>This study aimed to evaluate the potentiation of DOX and its effectiveness against the MCF-7 breast cancer cell line by encapsulating both DOX and CAM in PEGylated liposomes.</p><p><strong>Methods: </strong>PEGylated liposomes containing DOX and CAM were prepared using the thin film hydration method. The physicochemical properties of the liposomes, including average particle size, polydispersity index (PDI), and zeta potential, were characterized. Encapsulation efficiencies for CAM and DOX were assessed, and stability of the liposomes was evaluated over 9 days at room temperature. Cell viability was measured using an IC₅₀ assay, and P-gp expression levels were determined by ELISA.</p><p><strong>Results: </strong>The CAM/DOX-PEGylated liposomes exhibited optimal average particle size (238 ± 26.7 nm), PDI (0.29 ± 0.107), and zeta potential (-20.9 ± 2.17 mV). These liposomes maintained good stability regarding size and charge over 9 days. Encapsulation efficiencies were 81.05% for CAM and 78.13% for DOX. The IC50 value for CAM/DOX-PEGylated liposomes was 0.13 µM, representing a significant reduction compared to the physical mixture of CAM and DOX (0.25 µM) and free DOX (0.21 µM) against MCF-7 cells. ELISA analysis showed a reduction in P-gp expression of approximately 5% with CAM/DOX-PEGylated liposomes compared to 1.61% with free DOX.</p><p><strong>Conclusion: </strong>The results indicate that CAM encapsulated in PEGylated liposomes enhances the effectiveness of DOX against breast cancer cells, likely through the inhibition of p-glycoprotein. This approach may offer a promising strategy to overcome DOX resistance and improve chemotherapy outcomes.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241312561"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Mesothelioma Using Artificial Intelligence: A Scoping Review of Common Models and Applications.","authors":"Malihe Ram, Mohammad Reza Afrash, Khadijeh Moulaei, Erfan Esmaeeli, Mohadeseh Sadat Khorashadizadeh, Ali Garavand, Parastoo Amiri, Azam Sabahi","doi":"10.1177/15330338251341053","DOIUrl":"10.1177/15330338251341053","url":null,"abstract":"<p><p>IntroductionMesothelioma is a type of lung cancer caused by asbestos exposure, and early diagnosis is crucial for improving survival chances. Artificial intelligence offers a potential solution for the timely diagnosis and staging of the disease. This study aims to review the latest research conducted in artificial intelligence applications to predict mesothelioma.MethodsUntil April 24, 2023, PubMed, Scopus, and Web of Science databases were searched comprehensively for articles on artificial intelligence in mesothelioma management. The data was gathered using a standardized extraction form, and the findings were reported in figures and tables.ResultsOne hundred and seventy-three articles were identified from database searches, which were then reduced to 151 after eliminating duplicates. Finally, 19 articles were selected for inclusion in our study. The applications of artificial intelligence in these articles primarily focused on tumor diagnosis and classification (73.69%), followed by prevention and prognosis (21.05%) and tumor volumetric measurement of malignant pleural mesothelioma (5.26%). The most frequently used AI models include types of neural networks (NN), decision trees (DT), random forests (RF), logistic regression (LogR), Naïve Bayes (NB), and support vector machines (SVM). SVM, DT, and RF emerged as prominent models, achieving high accuracies ranging from 78.3% to 99.97%. Genetic algorithms, correlation-based algorithms, and Neural Networks were employed for risk factor identification and feature selection.ConclusionArtificial intelligence, particularly machine learning models such as neural networks, decision trees, support vector machines, and random forests, holds promise in predicting and managing mesothelioma, potentially enhancing early detection and improving patient outcomes.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251341053"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Deep Learning-Based Auto-Segmentation Results on Daily Kilovoltage, Megavoltage, and Cone Beam CT Images in Image-Guided Radiotherapy.","authors":"Zhixing Wang, Chengyu Shi, Carson Wong, Seyi M Oderinde, William T Watkins, Kun Qing, Bo Liu, Terence M Williams, An Liu, Chunhui Han","doi":"10.1177/15330338251344198","DOIUrl":"10.1177/15330338251344198","url":null,"abstract":"<p><p>IntroductionThis study aims to evaluate auto-segmentation results using deep learning-based auto-segmentation models on different online CT imaging modalities in image-guided radiotherapy.MethodsPhantom studies were first performed to benchmark image quality. Daily CT images for sixty patients were retrospectively retrieved from fan-beam kilovoltage CT (kVCT), kV cone-beam CT (kV-CBCT), and megavoltage CT (MVCT) scans. For each imaging modality, half of the patients received CT scans in the pelvic region, while the other half in the thoracic region. Deep learning auto-segmentation models using a convolutional neural network algorithm were used to generate organs-at-risk contours. Quantitative metrics were calculated to compare auto-segmentation results with manual contours.ResultsThe auto-segmentation contours on kVCT images showed statistically significant difference in Dice similarity coefficient (DSC), Jaccard similarity coefficient, sensitivity index, inclusiveness index, and the 95^th percentile Hausdorff distance, compared to those on kV-CBCT and MVCT images for most major organs. In the pelvic region, the largest difference in DSC was observed for the bowel volume with an average DSC of 0.84 ± 0.05, 0.35 ± 0.23, and 0.48 ± 0.27 for kVCT, kV-CBCT, and MVCT images, respectively (<i>p</i>-value < 0.05); in the thoracic region, the largest difference in DSC was found for the esophagus with an average DSC of 0.63 ± 0.16, 0.18 ± 0.13, and 0.22 ± 0.08 for kVCT, kV-CBCT, and MVCT images, respectively (<i>p</i>-value < 0.05).ConclusionDeep learning-based auto-segmentation models showed better agreement with manual contouring when using kVCT images compared to kV-CBCT or MVCT images. However, manual correction remains necessary after auto-segmentation with all imaging modalities, particularly for organs with limited contrast from surrounding tissues. These findings underscore the potential and limits in applying deep learning-based auto-segmentation models for adaptive radiotherapy.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251344198"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miR-10b as a Clinical Marker and a Therapeutic Target for Metastatic Breast Cancer.","authors":"Alan Halim, Bryan Kim, Elizabeth Kenyon, Anna Moore","doi":"10.1177/15330338251339256","DOIUrl":"10.1177/15330338251339256","url":null,"abstract":"<p><p>Despite advances in cancer detection and treatment, metastatic breast cancer continues to carry a poor prognosis due to the lack of diagnostic and therapeutic resources that are specific to the metastatic process. MicroRNA-10b (miR-10b) is a small, noncoding RNA that is the focus of many studies due to its unique role as a driver of metastasis. The pathways it is involved in and the properties it confers have been reviewed previously and, collectively, are suggestive of the potential of miR-10b as a clinical marker and as a therapeutic target specific to metastatic disease. With the goal of application of our understanding of miR-10b to the clinic, in this mini-review, we highlight the studies that support the utility of miR-10b for these translational purposes.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251339256"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spot-Scanning Confocal Photon Beams for Hypofractionated Brain Radiosurgery.","authors":"Lijun Ma, Shuang Luan, Nguyen Phuong Dang, Benjamin Ziemer, Steve Braunstein, Michael McDermott, Cheng Yu, Gabriel Zada, Eric L Chang","doi":"10.1177/15330338251342873","DOIUrl":"10.1177/15330338251342873","url":null,"abstract":"<p><p>IntroductionStereotactic radiosurgery (SRS) has been broadly used to treat brain tumors. In this study, a dose kernel-based spot scanning (DKSC) treatment delivery has been developed for hypofractionated brain SRS.MethodsDKSC treatments employs hundreds of confocal photon dose kernels. For such a delivery, a single continuous scanning path was first mapped within a 3D target volume, and then a series of dose kernels of variable sizes, shapes and beam weights were placed and then optimized along the path to produce highly conformal dose distributions. For implementation of DKSC delivery in a clinical setting, we specifically employed the Leksell Gamma Knife (LGK) system, where it is considered as the gold standard of modern SRS treatments.ResultsDKSC was successfully implemented for a patient treatment for the first time. General methodology as well as specific workflow and treatment planning caveats of implementing DKSC for the LGK is reported. To highlight the novelty of DKSC, we also compared DKSC against the conventional LGK-SRS treatment including its latest treatment planning optimization software.ConclusionDKSC has been demonstrated to be technically feasible, clinically implementable, and uniquely advantageous for hypofractionated brain SRS. Further studies are warranted toward testing DKSC for variable SRS modalities, different disease sites including extra-cranial lesions.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251342873"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}